Evidence map›Paper›PMID 37345327›Full record

ArticleTurkish journal of ophthalmology2023

A Case of Concurrent Acute Macular Neuroretinopathy and Paracentral Acute Middle Maculopathy Following Pfizer-BioNTech COVID-19 Vaccination.

Jale Menteş, Serhad Nalçacı, Cumali Değirmenci

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jale MenteşPrivate Clinic, İzmir, Türkiye.ORCID 0000-0003-3275-1127
Serhad NalçacıEge University Faculty of Medicine, Department of Ophthalmology, İzmir, Türkiye.ORCID 0000-0002-0401-9492
Cumali DeğirmenciEge University Faculty of Medicine, Department of Ophthalmology, İzmir, Türkiye.ORCID 0000-0002-8268-536X
Izmir University · TREge University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a 65-year-old woman who developed sudden and severe vision loss in her left eye one day after the administration of the second dose of COVID vaccine. The best corrected visual acuity in this eye was 1/10. Diffuse paracentral acute middle maculopathy was detected on spectral domain optical coherence tomography (OCT). OCT angiography images revealed concurrent vascular flow defects consistent with acute macular neuroretinopathy in the deep retinal capillary plexus and choriocapillaris layers. At the end of the six-month follow-up, there was no improvement in visual acuity, and atrophy and thinning developed in all layers of the retina.

Indexed as

COVID-19COVID-19 VaccinesMacular DegenerationRetinal DiseasesWhite Dot SyndromesAcute DiseaseAgedFemaleFluorescein AngiographyHumansVaccinationCOVID-19 VaccinesAcute macular neuroretinopathyoptical coherence tomography angiographyparacentral acute middle maculopathyPfizer-BioNTech COVID-19 vaccinespectral domain optical coherence tomography

Identifiers

PMID37345327
PMCPMC10286837
OpenAlexW4381598438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.